Compare
Hypha Labs, Inc. vs 20/20 Biolabs, Inc. vs NeoGenomics Inc vs UL Solutions Inc.
| Latest fiscal year | Hypha Labs, Inc. FUNI | 20/20 Biolabs, Inc. AIDX | NeoGenomics Inc NEO | UL Solutions Inc. ULS |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $2.05M | $727.33M | $3.05B |
| Revenue growth (YoY) | n/a | +16.7% | +10.1% | +6.4% |
| Gross margin | n/a | 29.6% | 43.2% | 49.5% (computed) |
| Operating margin | n/a | -162.9% | -15.9% | 17.1% |
| Net margin | n/a | -182.8% | -14.9% | 10.6% |
| Net income | -$3.10M | -$3.74M | -$108.03M | $325.00M |
| EPS (Diluted) | -$0.02 | -$0.76 | n/a | $1.60 |
| Operating cash flow | -$380.0K | -$1.92M | $5.23M | $600.00M |
| Free cash flow | -$412.9K | n/a | -$21.78M | $403.00M |
| Cash & equivalents | n/a | $1.03M | $159.62M | $295.00M |
| Total assets | $409.2K | $4.14M | $1.36B | $2.92B |
| Total liabilities | $2.51M | $4.16M | $523.27M | $1.63B |
| Shareholders' equity | -$2.44M | -$19.2K | $836.56M | $1.29B |
| Return on year-end equity | n/a | n/a | -12.9% | 25.1% |
| Shares outstanding | 147.12M | 5.44M | 128.15M | 201.03M |
Revenue, most recent five fiscal years
| Fiscal year | Hypha Labs, Inc. | 20/20 Biolabs, Inc. | NeoGenomics Inc | UL Solutions Inc. |
|---|---|---|---|---|
| Latest | $2.70M Ended 2022-09-30 | $2.05M Ended 2025-12-31 | $727.33M Ended 2025-12-31 | $3.05B Ended 2025-12-31 |
| 1 year earlier | $2.50M Ended 2021-09-30 | $1.75M Ended 2024-12-31 | $660.57M Ended 2024-12-31 | $2.87B Ended 2024-12-31 |
| 2 years earlier | $2.57M Ended 2020-09-30 | n/a | $591.64M Ended 2023-12-31 | $2.68B Ended 2023-12-31 |
| 3 years earlier | $2.55M Ended 2019-09-30 | n/a | $509.73M Ended 2022-12-31 | $2.52B Ended 2022-12-31 |
| 4 years earlier | $2.84M Ended 2018-09-30 | n/a | $484.33M Ended 2021-12-31 | n/a |